PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
0.13%
ROE below 50% of Drug Manufacturers - Specialty & Generic median of 0.56%. Jim Chanos would investigate potential structural issues or mismanagement.
0.10%
Positive ROA while Drug Manufacturers - Specialty & Generic median is negative. Philip Fisher would see if the firm has a stronger model than peers.
-1.00%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is -0.19%. Seth Klarman would investigate whether a turnaround is viable.
21.12%
Gross margin below 50% of Drug Manufacturers - Specialty & Generic median of 48.33%. Jim Chanos would suspect flawed products or pricing.
-35.25%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for a path to operational turnaround.
3.74%
Net margin of 3.74% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss would examine if modest profitability can expand.